Audit: QRS - Poly-γ-Glutamic Acid for Health & Longevity
Audit conducted on 24/09/2026 08:26 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All at-a-glance, protocol, time-to-effect, benefit, risk, gate, monitoring and qualitative entries trace to ER text (e.g., Therapeutic Protocol, Practical Considerations, Monitoring table, Conclusion). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried over: “short studies suggest it may help”, “Changed within 4–8 weeks in one trial”, “No established target”, “(no safety data)”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Severity words match the ER: Caution/Monitor/Additive per interaction; contraindications kept as avoid-populations. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER avoid-list, interactions from the interaction bullets, tiers from Expected Benefits / Potential Risks. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, author names, NCT IDs or brand names (e.g., Tums, Bioleaders, Ajinomoto omitted). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted tone mirrors the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms glossed where needed (CIN 1, mastocytosis, idiopathic, nattokinase). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal terms used (“orally”, “anticoagulants” for the ER’s “blood thinners”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate heads, tier labels and table headers are unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present; marker_# expanded to 1–9, qualitative_item_# to 1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Website spans (evidence_review, audit, full_review), footer and CSS match the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding a visible QRS section is empty; the empty High tiers are hidden per 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Immune protocol”, “Cervical-lesion protocol”, “Time of day”) and qualitative labels match ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Items are condensed to key facts; no section is extended with elaboration. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration is quoted, and its value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.9.23 matches QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-0924-0801 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Opus |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/24/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “the sticky substance in fermented soybeans, is a dietary supplement studied for immune, calcium and blood-sugar effects”. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words (script count). |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 7 ER avoid-populations listed. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers such as “(serum calcium above 10.5 mg/dL)”, “(high-grade lesions)”, “(no safety data)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names avoid-populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 14 ER interaction bullets represented. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists trimmed but retained for each item. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated; ER names interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Cervical-lesion protocol, immune protocol and time of day from ER Therapeutic Protocol. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist and are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | All three ER time-to-effect aspects (Practical Considerations) used. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered Medium (cervical) → Low (glucose/calcium) → Speculative (NK activity). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three time-to-effect aspects exist. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high hidden with display: none. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high hidden with display: none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 9 ER table biomarkers listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 5 ER qualitative markers listed. |
Issues 24/09/2026 08:26
Pass rate 100.00%. No issues found.
Issues 24/09/2026 08:22
- 1.1 — Ambiguous cervical assessment timing: Line 489, time_1_sub “Assessed at 12 weeks after a 4-week course” implies assessment 12 weeks after the course ended, whereas the ER (line 331) places it at week 12, eight weeks after the 4-week course ended.
Fixes 24/09/2026 08:22
- 1.1 — Ambiguous cervical assessment timing: Changed time_1_sub from “Assessed at 12 weeks after a 4-week course” to “Assessed at week 12, eight weeks after the 4-week course ended”, matching the ER timing.
Issues 24/09/2026 08:20
- 2.15 — Colloquial “blood thinners” term: The Nattokinase item in Key Interactions (QRS line 566) uses the consumer-grade term “blood thinners” instead of the clinical term “anticoagulants”.
Fixes 24/09/2026 08:20
- 2.15 — Colloquial “blood thinners” term: Replaced “blood thinners” with “anticoagulants” in the Nattokinase item of Key Interactions (QRS line 566).
Issues 24/09/2026 08:16
- 9.5 — Nattokinase parentheticals dropped: The Nattokinase item (line 566) omits the ER’s “(a clot-dissolving natto enzyme)” and the example drug list “(warfarin, apixaban)” for the added bleeding risk with blood thinners, dropping these parenthetical qualifiers entirely.
Fixes 24/09/2026 08:16
- 9.5 — Nattokinase parentheticals restored: Changed “Nattokinase and whole-natto extracts: Caution” to “Nattokinase (a clot-dissolving natto enzyme) and whole-natto extracts: Caution; added bleeding risk with blood thinners (warfarin, apixaban)”.
Issues 24/09/2026 08:12
- 1.1 / 7.4 — Unsupported “used for” claim: At-a-Glance (QRS line 433) says γ-PGA is “used for immune, calcium and blood-sugar support”; the ER presents it only as sold as a supplement and studied for these effects, never as used for blood-sugar support.
- 2.7 — Unglossed medical jargon: “Systemic mastocytosis” (QRS line 547) appears without the ER’s plain gloss “overactive allergy-cell disorder”, and “kDa” (line 461) is an unexplained unit abbreviation.
- 4.2 / 4.3 — Interaction label paraphrased: QRS line 558 shortens the ER bold label “Tetracycline and quinolone antibiotics, levothyroxine, bisphosphonates” to “Tetracyclines, quinolones, levothyroxine, bisphosphonates”.
Fixes 24/09/2026 08:12
- 1.1 / 7.4 — Unsupported “used for” claim: Changed At-a-Glance “used for immune, calcium and blood-sugar support” to “studied for immune, calcium and blood-sugar effects” (word count unchanged at 70).
- 2.7 — Unglossed medical jargon: Added the ER gloss “(overactive allergy-cell disorder)” after “Systemic mastocytosis” and replaced “kDa” with “kilodaltons” in action_2_sub.
- 4.2 / 4.3 — Interaction label paraphrased: Restored the ER label “Tetracycline and quinolone antibiotics, levothyroxine, bisphosphonates” and added ciprofloxacin to the examples (doxycycline, ciprofloxacin, alendronate).
Issues 24/09/2026 08:08
- 4.5 — Sheet exceeds one A4 page: Key Interactions (lines 556-569) keeps 14 items with full example-drug lists and long qualifiers, and Contraindications (lines 542-548) and action_3_sub (line 472) carry long explanatory text; with 9 monitoring rows the sheet runs well beyond one A4 page instead of being condensed.
Fixes 24/09/2026 08:08
- 4.5 — Condensed for one-page budget: Trimmed example-drug lists in 9 Key Interactions items to 1-2 examples each and shortened qualifier wording, shortened two Contraindications items (CIN 2 and jellyfish), and tightened action_3_sub and monitoring_cadence; all items and qualifiers were kept.
Issues 24/09/2026 08:05
- 2.7 — Avoidable jargon without gloss: Line 546 contraindication says “in place of excision or ablation” but drops the ER’s plain-language gloss “(surgical removal or destruction of the lesion)”; line 711 cadence uses “CIN 1” with no plain-language explanation anywhere on the sheet.
- 9.5 — Applicability qualifier dropped: Line 558 interaction item for tetracyclines, quinolones, levothyroxine and bisphosphonates omits that the interaction concerns “Calcium-containing γ-PGA products” (ER line 266).
Fixes 24/09/2026 08:05
- 2.7 — Restored plain-language glosses: Added the ER’s gloss “(surgical removal or destruction of the lesion)” after “excision or ablation” in the CIN 2 contraindication, and the ER’s explanation “(low-grade precancerous cell changes)” after “CIN 1” in the monitoring cadence.
- 9.5 — Restored applicability qualifier: Changed the tetracycline/quinolone/levothyroxine/bisphosphonate item from “Monitor” to “Monitor with calcium-containing γ-PGA products” per ER line 266.
Issues 24/09/2026 08:02
- 1.3 — Autoimmune caution qualifier dropped: Key Interactions line 564 lists immune-stimulating supplements as only “Additive”, omitting the ER’s “Caution in autoimmune disease” (ER line 278), which softens the ER claim.
Fixes 24/09/2026 08:02
- 1.3 — Autoimmune caution qualifier restored: Changed the immune-stimulating supplements interaction from “Additive” to “Additive; caution in autoimmune disease”, matching ER line 278.